The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma

By Ritchie D.   Seymour J.   Grigg A.   Roberts A.   Hoyt R.   Thompson S.   Szer J.   Prince H.  

Annals of Hematology, Vol. 86, Iss. 2, 2007-02 ,pp. : 101-105

Springer Publishing Company

Access to resources Recommend Favorite

Vanishing bile duct syndrome occurring after high-dose chemotherapy and autologous peripheral stem cell transplantation in a patient with Hodgkin’s disease

By Kömürcü Ş.   Özet A.   Altundag M.   Arpaci F.   Öztürk B.   Celasun B.   Tezcan Y.  

Annals of Hematology, Vol. 81, Iss. 1, 2002-01 ,pp. : 57-58

Springer Publishing Company

Access to resources Recommend Favorite

High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem-Cell Transplantation for the Treatment of Solid Tumors in Adults: A Critical Review

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 1, 2007-01 ,pp. : 65-82

Bentham Science Publishers

Access to resources Recommend Favorite

High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin’s lymphoma

By Ianni Mauro Di   Ballanti Stelvio   Iodice Giuseppe   Reale Antonia   Falzetti Franca   Minelli Olivia   Serio Gabriella   Martelli Massimo F   Dammacco Franco   Vacca Angelo   Ria Roberto  

Hematology, Vol. 17, Iss. 1, 2012-01 ,pp. : 23-27

Maney Publishing

Access to resources Recommend Favorite

Evaluation of relative anti-myeloma activity of high-dose melphalan followed by the first peripheral blood stem cell transplantation, as compared with the second transplantation, and to VAD chemotherapy

By Awedan A.   Krol M.   Blajer B.   Rokicka M.   Torosian T.   Urbanowska E.   Wiktor-Jedrzejczak W.  

Transplantation Proceedings, Vol. 35, Iss. 6, 2003-09 ,pp. : 2349-2351

Elsevier

Access to resources Recommend Favorite